A cross-sectional study of prescribing rates for SGLT2 inhibitors and GLP-1 receptor agonists among primary care clinics with and without embedded pharmacists.

Dave L Dixon¹, Teresa M Salgado², Amanda Robinson³, Salvatore Carbone⁴, Tyler D Wagner², Haroon Hyder⁵, Bryan Kirschner⁵, Kerri T Musselman⁶, Tonya M Buffington⁵, Roy T Sabo⁷

¹Center for Pharmacy Practice Innovation, Virginia Commonwealth University School of Pharmacy, Richmond, VA, United States; Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA, United States. Electronic address: DLDixon@vcu.edu.

²Center for Pharmacy Practice Innovation, Virginia Commonwealth University School of Pharmacy, Richmond, VA, United States; Department of Pharmacotherapy & Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA, United States.

³C. Kenneth and Dianne Wright Center for Clinical and Translational Research, Virginia Commonwealth University, Richmond, VA, United States.

⁴Nutrition Program, EVMS School of Health Professions, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA, United States; Easter Virginia Medical School Division of Endocrine and Metabolic Disorders, Strelitz Diabetes Center, Department of Medicine, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA, United States.

⁵Bon Secours Mercy Health, Richmond, VA, United States.

⁶Pharmacy Quality Solutions by Innovaccer, Durham, NC, United States.

⁷Center for Pharmacy Practice Innovation, Virginia Commonwealth University School of Pharmacy, Richmond, VA, United States; C. Kenneth and Dianne Wright Center for Clinical and Translational Research, Virginia Commonwealth University, Richmond, VA, United States; Department of Biostatistics, Virginia Commonwealth University School of Public Health, Richmond, VA, United States.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) are cardio- and kidney-protective, yet their uptake in clinical practice has been suboptimal. The association between pharmacists embedded in primary care clinics and prescribing rates of SGLT2i and GLP-1RA is unknown. OBJECTIVE: To compare the prescribing rates of SGLT2i and G…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.